These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34524212)

  • 21. Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).
    Luo N; Fonarow GC; Lippmann SJ; Mi X; Heidenreich PA; Yancy CW; Greiner MA; Hammill BG; Hardy NC; Turner SJ; Laskey WK; Curtis LH; Hernandez AF; Mentz RJ; O'Brien EC
    JACC Heart Fail; 2017 Apr; 5(4):305-309. PubMed ID: 28359417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined Left Ventricular Ejection Fraction and N-Terminal pro-B-type Natriuretic Peptide after Sacubitril/Valsartan for Predicting Outcomes in Patients with Heart Failure with Reduced Ejection Fraction.
    Fang CC; Jao YTFN
    Acta Cardiol Sin; 2023 Mar; 39(2):297-308. PubMed ID: 36911550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real-world study in Taiwan.
    Chang PC; Wang CL; Hsiao FC; Wen MS; Huang CY; Chou CC; Chu PH
    ESC Heart Fail; 2020 Oct; 7(5):3003-3012. PubMed ID: 32720478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.
    Burke RM; Lighthouse JK; Mickelsen DM; Small EM
    Circ Heart Fail; 2019 Apr; 12(4):e005565. PubMed ID: 30998392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Introduction of sacubitril/valsartan in primary care follow-up of heart failure: a prospective observational study (THESEUS).
    Dieterle T; Schaefer S; Meyer I; Ackermann G; Ahmed K; Hullin R
    ESC Heart Fail; 2020 Aug; 7(4):1626-1634. PubMed ID: 32369265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper.
    Ntalianis A; Chrysohoou C; Giannakoulas G; Giamouzis G; Karavidas A; Naka A; Papadopoulos CH; Patsilinakos S; Parissis J; Tziakas D; Kanakakis J
    Heart Fail Rev; 2022 Jan; 27(1):1-13. PubMed ID: 33931815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.
    DeVore AD; Mi X; Thomas L; Sharma PP; Albert NM; Butler J; Hernandez AF; Patterson JH; Spertus JA; Williams FB; Duffy CI; McCague K; Fonarow GC
    J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29895587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40.
    Zhao M; Xin Y; Li J; Cao X; Liu X
    Medicine (Baltimore); 2019 Sep; 98(39):e17296. PubMed ID: 31574852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review.
    Proudfoot C; Studer R; Rajput T; Jindal R; Agrawal R; Corda S; Senni M
    Int J Cardiol; 2021 May; 331():164-171. PubMed ID: 33545266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
    Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
    Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin receptor blocker neprilysin inhibitors.
    Usuda D; Higashikawa T; Hotchi Y; Usami K; Shimozawa S; Tokunaga S; Osugi I; Katou R; Ito S; Yoshizawa T; Asako S; Mishima K; Kondo A; Mizuno K; Takami H; Komatsu T; Oba J; Nomura T; Sugita M
    World J Cardiol; 2021 Aug; 13(8):325-339. PubMed ID: 34589168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction : A retrospective cohort study.
    De Vecchis R; Ariano C; Di Biase G; Noutsias M
    Herz; 2019 Aug; 44(5):425-432. PubMed ID: 29350254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.
    Han J; Chung F; Nguyen QL; Mody FV; Jackevicius CA
    Pharmacotherapy; 2019 Nov; 39(11):1053-1059. PubMed ID: 31498903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation.
    Chang HY; Feng AN; Fong MC; Hsueh CW; Lai WT; Huang KC; Chong E; Chen CN; Chang HC; Yin WH
    J Cardiol; 2019 Oct; 74(4):372-380. PubMed ID: 30982680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States.
    Zueger PM; Kumar VM; Harrington RL; Rigoni GC; Atwood A; DiDomenico RJ; Touchette DR
    Pharmacotherapy; 2018 May; 38(5):520-530. PubMed ID: 29601093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
    JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.
    Yandrapalli S; Andries G; Biswas M; Khera S
    Vasc Health Risk Manag; 2017; 13():369-382. PubMed ID: 29042791
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.